Congenital myasthenic syndromes and myasthenia

We present our experience in the treatment of 27 patients with Myasthenia Gravis anti-MuSK. We evaluated the treatments received, and the therapeutic response according to clinical and post-interventional status (PIS) of the Myasthenia Gravis Foundation of America (MGFA) at 6, 12, 24 months and current in a cohort of Musk-MG patient.

Source: Neuromuscular Disorders - September 6, 2018 Category: Neurology Authors: M. Rugiero, V. Salutto, V. Alvarez, M. Bettini, N. Genco, C. Mazia Source Type: research